Navigation Links
Bradmer receives FDA approval to proceed with Phase III clinical trial
Date:6/3/2008

Clinical and Manufacturing Plans Approved for Neuradiab(TM) Multi- center

Clinical Trial

TSX: BMR

TORONTO, June 3 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it has received notification from the United States Food and Drug Administration (FDA) that it may proceed with the launch of its proposed Phase III trial evaluating Neuradiab(TM) as a front-line therapy for glioblastoma multiforme (GBM), the most common and advanced form of primary brain cancer. To support this approval, Bradmer previously submitted the Chemistry, Manufacturing and Control (CMC) dossier, as well as the Clinical Protocol and related trial design and execution documents to the FDA for review. The FDA determined that the CMC dossier and the Clinical Protocol contained the necessary information to support the execution of the Phase III multi-center clinical trial developed by Bradmer.

"With this positive response from the FDA, we are now in a position to begin treating patients with this potentially vital new therapy for glioblastoma multiforme," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "This is a major milestone for Bradmer. We will now turn all of our collective efforts to supporting the clinical trial sites for the successful execution of this landmark study and look forward to enrolling patients at our initial centers."

The Phase III trial, named the GLASS-ART Trial, is currently screening for patients and will investigate Neuradiab(TM) as an adjuvant therapy to surgery, external beam radiation and temozolomide in 760 patients with newly diagnosed glioblastoma multiforme. The randomized trial is expected to be conducted at leading brain tumor treatment centers across the United States.

About Neuradiab(TM)

Neuradiab(TM) is
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Bradmer announces 2008 first quarter operational and financial results
2. Bradmer announces new additions to management team
3. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
4. Notice of Bradmer Pharmaceuticals Conference Call
5. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
6. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
7. Bradmer announces additions to Scientific Advisory Board
8. Bradmer Medical Isotope Supply For Phase III Trial Secure
9. Bradmer to present at Rodman & Renshaw Healthcare Conference
10. Bradmer provides Phase III Neuradiab trial update and guidance
11. Bradmer announces management changes
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 1Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 2Research Reveals How Mitochondrial Gene Defects Impair Respiration Other Major Life Functions 58280 3Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 1Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 2Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 3Encouraging HIV AIDS Vaccine Trial Results Support GeoVax Labs Inc Strategy 14265 4Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 1Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 2Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 3Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 4Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 5Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 6Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 7Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 8Reportlinker Adds In Vitro Diagnostics in a Recession 3A IVD Market Forecasts Analysis and Success Strategies Report 14260 9